The most recent trading session ended with Boston Scientific (BSX) standing at $98.66, reflecting a +0.5% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 1%. Meanwhile, the Dow experienced a rise of 0.78%, and the technology-dominated Nasdaq saw an increase of 1.51%.
Coming into today, shares of the medical device manufacturer had gained 10.73% in the past month. In that same time, the Medical sector lost 1.36%, while the S&P 500 lost 2.14%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. The company plans to announce its earnings on February 5, 2025. The company's earnings per share (EPS) are projected to be $0.65, reflecting a 18.18% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $4.4 billion, indicating a 18.13% growth compared to the corresponding quarter of the prior year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.07% downward. As of now, Boston Scientific holds a Zacks Rank of #3 (Hold).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 35.44. This denotes a premium relative to the industry's average Forward P/E of 18.22.
We can additionally observe that BSX currently boasts a PEG ratio of 2.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.19 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 77, positioning it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpBoston Scientific Corporation (BSX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
